{"id":3143,"date":"2024-03-05T08:30:36","date_gmt":"2024-03-05T07:30:36","guid":{"rendered":"https:\/\/invivo.partners\/?p=3143"},"modified":"2024-03-05T08:44:31","modified_gmt":"2024-03-05T07:44:31","slug":"invivo-partners-is-preparing-to-launch-a-e100m-invivo-ventures-iii-fund-to-invest-in-leading-edge-life-sciences","status":"publish","type":"post","link":"https:\/\/invivo.partners\/ca\/2024\/03\/05\/invivo-partners-is-preparing-to-launch-a-e100m-invivo-ventures-iii-fund-to-invest-in-leading-edge-life-sciences\/","title":{"rendered":"Invivo Partners is preparing to launch a \u20ac100M Invivo Ventures III Fund to invest in Leading-Edge Life Sciences"},"content":{"rendered":"<p style=\"text-align: center;\"><img loading=\"lazy\" decoding=\"async\" class=\" wp-image-3139 alignleft\" src=\"https:\/\/invivo.partners\/wp-content\/uploads\/2024\/03\/image002-300x183.jpg\" alt=\"\" width=\"376\" height=\"230\" srcset=\"https:\/\/invivo.partners\/wp-content\/uploads\/2024\/03\/image002-300x183.jpg 300w, https:\/\/invivo.partners\/wp-content\/uploads\/2024\/03\/image002-1024x623.jpg 1024w, https:\/\/invivo.partners\/wp-content\/uploads\/2024\/03\/image002-768x468.jpg 768w, https:\/\/invivo.partners\/wp-content\/uploads\/2024\/03\/image002-1536x935.jpg 1536w, https:\/\/invivo.partners\/wp-content\/uploads\/2024\/03\/image002-2048x1247.jpg 2048w, https:\/\/invivo.partners\/wp-content\/uploads\/2024\/03\/image002-280x170.jpg 280w, https:\/\/invivo.partners\/wp-content\/uploads\/2024\/03\/image002-1170x712.jpg 1170w\" sizes=\"auto, (max-width: 376px) 100vw, 376px\" \/><strong>Laura Rodr\u00edguez is promoted to Partner, reinforcing Invivo\u2019s commitment <\/strong><strong>to catalyzing life science breakthroughs<\/strong><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>Barcelona, Spain, March 5th, 2024<\/p>\n<p>&nbsp;<\/p>\n<p>Invivo Partners is preparing the launch of its latest fund, Invivo Ventures III, with a target volume of \u20ac100 million. This new fund underscores Invivo Partners&#8217; commitment to revolutionizing the life sciences sector, particularly at the intersection of advanced therapies, synthetic biology, and artificial intelligence.<\/p>\n<p>Invivo Partners has established a solid track record of successful exits with the acquisitions of Sanifit and Versantis in 2022, and substantial funding rounds recently closed, such as Arthex\u2019s \u20ac42M Series B round in May 2023 and Corteria\u2019s \u20ac65M Series A in September 2023. Invivo Ventures III is strategically designed to propel the emergent field of synthetic biology, a domain where Invivo has already established a formidable presence through investments in pioneering companies. These investments reflect Invivo&#8217;s expertise and belief in the transformative potential of deep tech to address critical healthcare challenges.<\/p>\n<p>With the launch of this new fund, Invivo Partners is delighted to announce the promotion of Laura Rodr\u00edguez from Principal to Partner, following a robust tenure in venture capital. With a PhD in Biotechnology and a strong background in oncology gene therapy research, Laura has contributed to the advancement of the biotech sector through her work in tech transfer at the Vall d&#8217;Hebron Hospital Research Institute and as a board director for portfolio companies. Laura is committed to fostering the biotech ecosystem, actively engaging as a mentor, evaluator, and board director, contributing significantly to the innovation ecosystem.<\/p>\n<p>The fund&#8217;s focus aligns with Invivo&#8217;s mission to support early-stage life science companies that are at the forefront of innovation. With a majority of private investors and the backing of significant institutional investors, Invivo Ventures III is poised to make a substantial impact in the life sciences ecosystem.<\/p>\n<p>\u201cIn these challenging economic times, this closing speaks volumes about the strength of our investments and our team&#8217;s dedication. It&#8217;s an absolute privilege to welcome Laura to our partnership; her extraordinary contributions will undoubtedly propel us to new heights. As we embark on this journey, our ultimate goal remains unwavering: to make a meaningful impact on patients&#8217; lives. They are the heart of our mission\u201d said Luis Pareras, Managing Partner.<\/p>\n<p>\u00abThe launch of Invivo Ventures III is a natural progression of our commitment to nurturing groundbreaking life science companies. It has been more than 12 years since we started this journey, with more than 15 portfolio companies invested in. With this third fund, we are more optimistic than ever about the potential opportunities awaiting in the field of life sciences.\u00bb said Albert Ferrer, Partner.<\/p>\n<p>\u00abI am deeply honored by the promotion to Partner at such a pivotal moment for Invivo Partners. This opportunity to contribute to the building of new companies that push the boundaries of innovation in advanced therapies is a challenge I accept with both gratitude and eagerness.\u00bb said Laura Rodr\u00edguez, Partner.<\/p>\n<p>Invivo Partners continues to be a beacon of innovation and progress in the venture capital landscape, especially in the early-stage life sciences sector. The firm&#8217;s track record of successful investments and its strategic focus on areas like synthetic biology and advanced therapies underscore its commitment to driving meaningful change and progress in healthcare.<\/p>\n<p><strong>About Invivo Partners<\/strong><br \/>\nInvivo Partners, a Spanish venture capital firm co-founded by Dr. Luis Pareras and Albert Ferrer, invests in early-stage life science companies at the intersection of advanced therapies, synthetic biology, and artificial intelligence. It has managed so far two funds supported by a majority of private investors and a number of institutional investors such as the European Investment Fund (EIF), Fond-ICO Global, the Catalan Finance Institute, the Valencia Institute of Finance and the<br \/>\nBarcelona City Council.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Laura Rodr\u00edguez is promoted to Partner, reinforcing Invivo\u2019s commitment to catalyzing life science breakthroughs &nbsp; &nbsp; Barcelona, Spain, March 5th, 2024 &nbsp; Invivo Partners is preparing the launch of its latest fund, Invivo Ventures III, with a target volume of \u20ac100 million. This new fund underscores Invivo Partners&#8217; commitment to revolutionizing the life sciences sector,<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[516],"tags":[],"class_list":["post-3143","post","type-post","status-publish","format-standard","hentry","category-noticias-ca"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Invivo Partners is preparing to launch a \u20ac100M Invivo Ventures III Fund to invest in Leading-Edge Life Sciences - Invivo Partners<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/invivo.partners\/ca\/2024\/03\/05\/invivo-partners-is-preparing-to-launch-a-e100m-invivo-ventures-iii-fund-to-invest-in-leading-edge-life-sciences\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Invivo Partners is preparing to launch a \u20ac100M Invivo Ventures III Fund to invest in Leading-Edge Life Sciences - Invivo Partners\" \/>\n<meta property=\"og:description\" content=\"Laura Rodr\u00edguez is promoted to Partner, reinforcing Invivo\u2019s commitment to catalyzing life science breakthroughs &nbsp; &nbsp; Barcelona, Spain, March 5th, 2024 &nbsp; Invivo Partners is preparing the launch of its latest fund, Invivo Ventures III, with a target volume of \u20ac100 million. This new fund underscores Invivo Partners&#8217; commitment to revolutionizing the life sciences sector,\" \/>\n<meta property=\"og:url\" content=\"https:\/\/invivo.partners\/ca\/2024\/03\/05\/invivo-partners-is-preparing-to-launch-a-e100m-invivo-ventures-iii-fund-to-invest-in-leading-edge-life-sciences\/\" \/>\n<meta property=\"og:site_name\" content=\"Invivo Partners\" \/>\n<meta property=\"article:published_time\" content=\"2024-03-05T07:30:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-03-05T07:44:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/invivo.partners\/wp-content\/uploads\/2024\/03\/image002-300x183.jpg\" \/>\n<meta name=\"author\" content=\"Bego\u00f1a Aguirre\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"Bego\u00f1a Aguirre\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minuts\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/invivo.partners\/ca\/2024\/03\/05\/invivo-partners-is-preparing-to-launch-a-e100m-invivo-ventures-iii-fund-to-invest-in-leading-edge-life-sciences\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/invivo.partners\/ca\/2024\/03\/05\/invivo-partners-is-preparing-to-launch-a-e100m-invivo-ventures-iii-fund-to-invest-in-leading-edge-life-sciences\/\"},\"author\":{\"name\":\"Bego\u00f1a Aguirre\",\"@id\":\"https:\/\/invivo.partners\/#\/schema\/person\/1dd96371a3f6bd32a0a04f752b53f1ee\"},\"headline\":\"Invivo Partners is preparing to launch a \u20ac100M Invivo Ventures III Fund to invest in Leading-Edge Life Sciences\",\"datePublished\":\"2024-03-05T07:30:36+00:00\",\"dateModified\":\"2024-03-05T07:44:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/invivo.partners\/ca\/2024\/03\/05\/invivo-partners-is-preparing-to-launch-a-e100m-invivo-ventures-iii-fund-to-invest-in-leading-edge-life-sciences\/\"},\"wordCount\":643,\"publisher\":{\"@id\":\"https:\/\/invivo.partners\/#organization\"},\"articleSection\":[\"Noticias\"],\"inLanguage\":\"ca\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/invivo.partners\/ca\/2024\/03\/05\/invivo-partners-is-preparing-to-launch-a-e100m-invivo-ventures-iii-fund-to-invest-in-leading-edge-life-sciences\/\",\"url\":\"https:\/\/invivo.partners\/ca\/2024\/03\/05\/invivo-partners-is-preparing-to-launch-a-e100m-invivo-ventures-iii-fund-to-invest-in-leading-edge-life-sciences\/\",\"name\":\"Invivo Partners is preparing to launch a \u20ac100M Invivo Ventures III Fund to invest in Leading-Edge Life Sciences - Invivo Partners\",\"isPartOf\":{\"@id\":\"https:\/\/invivo.partners\/#website\"},\"datePublished\":\"2024-03-05T07:30:36+00:00\",\"dateModified\":\"2024-03-05T07:44:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/invivo.partners\/ca\/2024\/03\/05\/invivo-partners-is-preparing-to-launch-a-e100m-invivo-ventures-iii-fund-to-invest-in-leading-edge-life-sciences\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/invivo.partners\/ca\/2024\/03\/05\/invivo-partners-is-preparing-to-launch-a-e100m-invivo-ventures-iii-fund-to-invest-in-leading-edge-life-sciences\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/invivo.partners\/ca\/2024\/03\/05\/invivo-partners-is-preparing-to-launch-a-e100m-invivo-ventures-iii-fund-to-invest-in-leading-edge-life-sciences\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/invivo.partners\/ca\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Invivo Partners is preparing to launch a \u20ac100M Invivo Ventures III Fund to invest in Leading-Edge Life Sciences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/invivo.partners\/#website\",\"url\":\"https:\/\/invivo.partners\/\",\"name\":\"Invivo Capital\",\"description\":\"Somos un fondo de capital riesgo especializado en proyectos early-stage del sector salud.\",\"publisher\":{\"@id\":\"https:\/\/invivo.partners\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/invivo.partners\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"ca\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/invivo.partners\/#organization\",\"name\":\"Invivo Capital\",\"url\":\"https:\/\/invivo.partners\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/invivo.partners\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg\",\"contentUrl\":\"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg\",\"width\":1200,\"height\":630,\"caption\":\"Invivo Capital\"},\"image\":{\"@id\":\"https:\/\/invivo.partners\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/invivo.partners\/#\/schema\/person\/1dd96371a3f6bd32a0a04f752b53f1ee\",\"name\":\"Bego\u00f1a Aguirre\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/invivo.partners\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/460068a94be660c8b15fdf3032d7898737605cd317d277a63782d52d9fd88201?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/460068a94be660c8b15fdf3032d7898737605cd317d277a63782d52d9fd88201?s=96&d=mm&r=g\",\"caption\":\"Bego\u00f1a Aguirre\"},\"url\":\"https:\/\/invivo.partners\/ca\/author\/bego\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Invivo Partners is preparing to launch a \u20ac100M Invivo Ventures III Fund to invest in Leading-Edge Life Sciences - Invivo Partners","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/invivo.partners\/ca\/2024\/03\/05\/invivo-partners-is-preparing-to-launch-a-e100m-invivo-ventures-iii-fund-to-invest-in-leading-edge-life-sciences\/","og_locale":"ca_ES","og_type":"article","og_title":"Invivo Partners is preparing to launch a \u20ac100M Invivo Ventures III Fund to invest in Leading-Edge Life Sciences - Invivo Partners","og_description":"Laura Rodr\u00edguez is promoted to Partner, reinforcing Invivo\u2019s commitment to catalyzing life science breakthroughs &nbsp; &nbsp; Barcelona, Spain, March 5th, 2024 &nbsp; Invivo Partners is preparing the launch of its latest fund, Invivo Ventures III, with a target volume of \u20ac100 million. This new fund underscores Invivo Partners&#8217; commitment to revolutionizing the life sciences sector,","og_url":"https:\/\/invivo.partners\/ca\/2024\/03\/05\/invivo-partners-is-preparing-to-launch-a-e100m-invivo-ventures-iii-fund-to-invest-in-leading-edge-life-sciences\/","og_site_name":"Invivo Partners","article_published_time":"2024-03-05T07:30:36+00:00","article_modified_time":"2024-03-05T07:44:31+00:00","og_image":[{"url":"https:\/\/invivo.partners\/wp-content\/uploads\/2024\/03\/image002-300x183.jpg"}],"author":"Bego\u00f1a Aguirre","twitter_card":"summary_large_image","twitter_misc":{"Escrit per":"Bego\u00f1a Aguirre","Temps estimat de lectura":"4 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/invivo.partners\/ca\/2024\/03\/05\/invivo-partners-is-preparing-to-launch-a-e100m-invivo-ventures-iii-fund-to-invest-in-leading-edge-life-sciences\/#article","isPartOf":{"@id":"https:\/\/invivo.partners\/ca\/2024\/03\/05\/invivo-partners-is-preparing-to-launch-a-e100m-invivo-ventures-iii-fund-to-invest-in-leading-edge-life-sciences\/"},"author":{"name":"Bego\u00f1a Aguirre","@id":"https:\/\/invivo.partners\/#\/schema\/person\/1dd96371a3f6bd32a0a04f752b53f1ee"},"headline":"Invivo Partners is preparing to launch a \u20ac100M Invivo Ventures III Fund to invest in Leading-Edge Life Sciences","datePublished":"2024-03-05T07:30:36+00:00","dateModified":"2024-03-05T07:44:31+00:00","mainEntityOfPage":{"@id":"https:\/\/invivo.partners\/ca\/2024\/03\/05\/invivo-partners-is-preparing-to-launch-a-e100m-invivo-ventures-iii-fund-to-invest-in-leading-edge-life-sciences\/"},"wordCount":643,"publisher":{"@id":"https:\/\/invivo.partners\/#organization"},"articleSection":["Noticias"],"inLanguage":"ca"},{"@type":"WebPage","@id":"https:\/\/invivo.partners\/ca\/2024\/03\/05\/invivo-partners-is-preparing-to-launch-a-e100m-invivo-ventures-iii-fund-to-invest-in-leading-edge-life-sciences\/","url":"https:\/\/invivo.partners\/ca\/2024\/03\/05\/invivo-partners-is-preparing-to-launch-a-e100m-invivo-ventures-iii-fund-to-invest-in-leading-edge-life-sciences\/","name":"Invivo Partners is preparing to launch a \u20ac100M Invivo Ventures III Fund to invest in Leading-Edge Life Sciences - Invivo Partners","isPartOf":{"@id":"https:\/\/invivo.partners\/#website"},"datePublished":"2024-03-05T07:30:36+00:00","dateModified":"2024-03-05T07:44:31+00:00","breadcrumb":{"@id":"https:\/\/invivo.partners\/ca\/2024\/03\/05\/invivo-partners-is-preparing-to-launch-a-e100m-invivo-ventures-iii-fund-to-invest-in-leading-edge-life-sciences\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/invivo.partners\/ca\/2024\/03\/05\/invivo-partners-is-preparing-to-launch-a-e100m-invivo-ventures-iii-fund-to-invest-in-leading-edge-life-sciences\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/invivo.partners\/ca\/2024\/03\/05\/invivo-partners-is-preparing-to-launch-a-e100m-invivo-ventures-iii-fund-to-invest-in-leading-edge-life-sciences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/invivo.partners\/ca\/"},{"@type":"ListItem","position":2,"name":"Invivo Partners is preparing to launch a \u20ac100M Invivo Ventures III Fund to invest in Leading-Edge Life Sciences"}]},{"@type":"WebSite","@id":"https:\/\/invivo.partners\/#website","url":"https:\/\/invivo.partners\/","name":"Invivo Capital","description":"Somos un fondo de capital riesgo especializado en proyectos early-stage del sector salud.","publisher":{"@id":"https:\/\/invivo.partners\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/invivo.partners\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"ca"},{"@type":"Organization","@id":"https:\/\/invivo.partners\/#organization","name":"Invivo Capital","url":"https:\/\/invivo.partners\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/invivo.partners\/#\/schema\/logo\/image\/","url":"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg","contentUrl":"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg","width":1200,"height":630,"caption":"Invivo Capital"},"image":{"@id":"https:\/\/invivo.partners\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/invivo.partners\/#\/schema\/person\/1dd96371a3f6bd32a0a04f752b53f1ee","name":"Bego\u00f1a Aguirre","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/invivo.partners\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/460068a94be660c8b15fdf3032d7898737605cd317d277a63782d52d9fd88201?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/460068a94be660c8b15fdf3032d7898737605cd317d277a63782d52d9fd88201?s=96&d=mm&r=g","caption":"Bego\u00f1a Aguirre"},"url":"https:\/\/invivo.partners\/ca\/author\/bego\/"}]}},"_links":{"self":[{"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/posts\/3143","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/comments?post=3143"}],"version-history":[{"count":11,"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/posts\/3143\/revisions"}],"predecessor-version":[{"id":3258,"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/posts\/3143\/revisions\/3258"}],"wp:attachment":[{"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/media?parent=3143"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/categories?post=3143"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/tags?post=3143"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}